XML 62 R44.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting [Abstract] |
Net Sales and Operating Profit by Segment |
|  | 2023 |  | 2022 |  | 2021
Net sales |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |
North America(1) |  | $ | 3,925 |  |  | $ | 3,816 |  |  | $ | 3,694 |
Latin America |  | 4,640 |  |  | 3,982 |  |  | 3,663 |
Europe |  | 2,737 |  |  | 2,548 |  |  | 2,841 |
Asia Pacific |  | 2,782 |  |  | 2,826 |  |  | 2,867 |
Africa/Eurasia |  | 1,083 |  |  | 1,082 |  |  | 1,045 |
Total Oral, Personal and Home Care |  | 15,167 |  |  | 14,254 |  |  | 14,110 |
Pet Nutrition(2) |  | 4,290 |  |  | 3,713 |  |  | 3,311 |
Total Net sales |  | $ | 19,457 |  |  | $ | 17,967 |  |  | $ | 17,421 |
_________ (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,625, $3,511 and $3,391 in 2023, 2022 and 2021, respectively. (2) Net sales in the U.S. for Pet Nutrition were $2,918, $2,432 and $2,018 in 2023, 2022 and 2021, respectively.
|  | 2023 |  | 2022 |  | 2021
Operating profit |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |
North America |  | $ | 892 |  |  | $ | 761 |  |  | $ | 754 |
Latin America |  | 1,417 |  |  | 1,108 |  |  | 1,012 |
Europe |  | 552 |  |  | 514 |  |  | 682 |
Asia Pacific |  | 767 |  |  | 737 |  |  | 844 |
Africa/Eurasia |  | 254 |  |  | 228 |  |  | 203 |
Total Oral, Personal and Home Care |  | 3,882 |  |  | 3,348 |  |  | 3,495 |
Pet Nutrition |  | 806 |  |  | 850 |  |  | 901 |
Corporate |  | (704) |  |  | (1,305) |  |  | (1,064) |
Total Operating profit |  | $ | 3,984 |  |  | $ | 2,893 |  |  | $ | 3,332 |
|  | 2023 |  | 2022 |  | 2021
Capital expenditures |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |
North America |  | $ | 46 |  |  | $ | 66 |  |  | $ | 87 |
Latin America |  | 146 |  |  | 121 |  |  | 118 |
Europe |  | 44 |  |  | 31 |  |  | 44 |
Asia Pacific |  | 65 |  |  | 60 |  |  | 50 |
Africa/Eurasia |  | 10 |  |  | 30 |  |  | 33 |
Total Oral, Personal and Home Care |  | 311 |  |  | 308 |  |  | 332 |
Pet Nutrition |  | 301 |  |  | 297 |  |  | 147 |
Corporate |  | 93 |  |  | 91 |  |  | 88 |
Total Capital expenditures |  | $ | 705 |  |  | $ | 696 |  |  | $ | 567 |
|  | 2023 |  | 2022 |  | 2021
Depreciation and amortization |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |
North America |  | $ | 99 |  |  | $ | 106 |  |  | $ | 104 |
Latin America |  | 98 |  |  | 93 |  |  | 88 |
Europe |  | 82 |  |  | 90 |  |  | 98 |
Asia Pacific |  | 84 |  |  | 89 |  |  | 96 |
Africa/Eurasia |  | 9 |  |  | 9 |  |  | 9 |
Total Oral, Personal and Home Care |  | 372 |  |  | 387 |  |  | 395 |
Pet Nutrition |  | 101 |  |  | 65 |  |  | 62 |
Corporate |  | 94 |  |  | 93 |  |  | 99 |
Total Depreciation and amortization |  | $ | 567 |  |  | $ | 545 |  |  | $ | 556 |
|  | 2023 |  | 2022 |  |
Identifiable assets |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |
North America |  | $ | 3,924 |  |  | $ | 4,012 |  |  |
Latin America |  | 2,987 |  |  | 2,603 |  |  |
Europe |  | 3,542 |  |  | 3,457 |  |  |
Asia Pacific |  | 2,071 |  |  | 2,085 |  |  |
Africa/Eurasia |  | 698 |  |  | 694 |  |  |
Total Oral, Personal and Home Care |  | 13,222 |  |  | 12,851 |  |  |
Pet Nutrition |  | 3,084 |  |  | 2,804 |  |  |
Corporate(1) |  | 87 |  |  | 76 |  |  |
Total Identifiable assets |  | $ | 16,393 |  |  | $ | 15,731 |  |  |
____________ (1)In 2023, Corporate identifiable assets primarily consisted of investments in equity securities (98%). In 2022, Corporate identifiable assets primarily consisted of investments in equity securities (95%).
|  | 2023 |  | 2022 |  |
Long-lived assets(1) |  |  |  |  |  |
United States |  | $ | 2,733 |  |  | $ | 2,569 |  |  |
International |  | 2,340 |  |  | 2,216 |  |  |
Total Long-lived assets |  | $ | 5,073 |  |  | $ | 4,785 |  |  |
____________ (1)Long-lived assets include Property, plant and equipment, net and lease right-of-use assets.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration